(Q45259361)

11 December 2017

title

CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations (English)

1 reference

11 December 2017

Rujia Xie

1

1 reference

11 December 2017

Lai Hock Tan

2

1 reference

11 December 2017

Emery C Polasek

3

1 reference

11 December 2017

Catherine Hong

4

1 reference

11 December 2017

Melvyn Teillol-Foo

5

1 reference

11 December 2017

Toufigh Gordi

6

1 reference

11 December 2017

Amarnath Sharma

7

1 reference

11 December 2017

Dana J Nickens

8

1 reference

11 December 2017

Tomoko Arakawa

9

1 reference

11 December 2017

Dean W Knuth

10

1 reference

11 December 2017

Edward J Antal

11

1 reference

11 December 2017

publication date

1 March 2005

1 reference

The Journal of Clinical Pharmacology

11 December 2017

published in

1 reference

11 December 2017

volume

45

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

352-356

1 reference

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Influence of race or ethnicity on pharmacokinetics of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

The effect of rifampin administration on the disposition of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Effect of St John's wort on the pharmacokinetics of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

First-pass metabolism of midazolam by the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004273320

21 January 2018

Identifiers

DOI

10.1177/0091270004273320

1 reference

11 December 2017

1 reference